Liposomal honokiol, a promising agent for treatment of cisplatin-resistant human ovarian cancer

By Luo Hong  

Journal of Cancer Research and Clinical Oncology, Vol. 134, Iss. 9, 2008-09 ,pp. : 937-945

Springer Publishing Company

Access to resources Recommend Favorite

The potential for LOXL2 as a target for future cancer treatment

By Barker Holly E   Erler Janine T  

Future Oncology, Vol. 7, Iss. 6, 2011-06 ,pp. : 707-710

Future Medicine

Access to resources Recommend Favorite

Knockdown of survivin contributes to antitumor activity in cisplatin-resistant ovarian cancer cells

By        

Molecular Medicine Reports, Vol. 7, Iss. 2, 2013-01 ,pp. : 425-430

Spandidos Publications

Access to resources Recommend Favorite

Antitumor properties of salinomycin on cisplatin-resistant human ovarian cancer cells in vitro and in vivo: involvement of p38 MAPK activation

By            

Oncology Reports, Vol. 29, Iss. 4, 2013-01 ,pp. : 1371-1378

Spandidos Publications

Access to resources Recommend Favorite

Metformin combined with p38 MAPK inhibitor improves cisplatin sensitivity in cisplatinresistant ovarian cancer

By            

Molecular Medicine Reports, Vol. 10, Iss. 5, 2014-01 ,pp. : 2346-2350

Spandidos Publications

Access to resources Recommend Favorite